Published in Methods on November 04, 2015
Biologically Relevant Heterogeneity: Metrics and Practical Insights. SLAS Discov (2017) 0.75
Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics (2003) 100.88
A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays. J Biomol Screen (1999) 32.67
Transcriptome-wide noise controls lineage choice in mammalian progenitor cells. Nature (2008) 7.60
Intra-tumour heterogeneity: a looking glass for cancer? Nat Rev Cancer (2012) 6.82
Cancer cells display profound intra- and interline variation following prolonged exposure to antimitotic drugs. Cancer Cell (2008) 6.62
Tumour heterogeneity and cancer cell plasticity. Nature (2013) 5.47
Multidimensional drug profiling by automated microscopy. Science (2004) 5.45
Genome-wide recessive genetic screening in mammalian cells with a lentiviral CRISPR-guide RNA library. Nat Biotechnol (2013) 4.72
Cellular heterogeneity: do differences make a difference? Cell (2010) 3.57
Circumventing cancer drug resistance in the era of personalized medicine. Cancer Discov (2012) 3.25
Proof without prejudice: use of the Kolmogorov-Smirnov test for the analysis of histograms from flow systems and other sources. J Histochem Cytochem (1977) 2.81
Addressing genetic tumor heterogeneity through computationally predictive combination therapy. Cancer Discov (2013) 2.59
Measurement of single-cell dynamics. Nature (2010) 2.55
Non-genetic heterogeneity of cells in development: more than just noise. Development (2009) 2.48
Origins of regulated cell-to-cell variability. Nat Rev Mol Cell Biol (2011) 2.15
Characterizing heterogeneous cellular responses to perturbations. Proc Natl Acad Sci U S A (2008) 2.03
Origins and implications of pluripotent stem cell variability and heterogeneity. Nat Rev Mol Cell Biol (2013) 1.91
A pair of new statistical parameters for quality control in RNA interference high-throughput screening assays. Genomics (2007) 1.79
Patterns of basal signaling heterogeneity can distinguish cellular populations with different drug sensitivities. Mol Syst Biol (2010) 1.77
Integrated microfluidic bioprocessor for single-cell gene expression analysis. Proc Natl Acad Sci U S A (2008) 1.73
Messy biology and the origins of evolutionary innovations. Nat Chem Biol (2010) 1.61
Identifying and quantifying heterogeneity in high content analysis: application of heterogeneity indices to drug discovery. PLoS One (2014) 1.58
Advances in high content screening for drug discovery. Assay Drug Dev Technol (2003) 1.55
Heterogeneity in the physiological states and pharmacological responses of differentiating 3T3-L1 preadipocytes. J Cell Biol (2009) 1.51
Two new human tumor cell lines derived from squamous cell carcinomas of the tongue: establishment, characterization and response to cytotoxic treatment. Eur J Cancer Clin Oncol (1988) 1.50
A non-genetic basis for cancer progression and metastasis: self-organizing attractors in cell regulatory networks. Breast Dis (2007) 1.49
Cell Biology. Using cell-to-cell variability--a new era in molecular biology. Science (2012) 1.30
Evaluating tumor heterogeneity in immunohistochemistry-stained breast cancer tissue. Lab Invest (2012) 1.22
Phylogenetic quantification of intra-tumour heterogeneity. PLoS Comput Biol (2014) 1.21
An approach for extensibly profiling the molecular states of cellular subpopulations. Nat Methods (2009) 1.18
New horizons in tumor microenvironment biology: challenges and opportunities. BMC Med (2015) 1.12
Workflow and metrics for image quality control in large-scale high-content screens. J Biomol Screen (2011) 1.08
Cell-based screening using high-throughput flow cytometry. Assay Drug Dev Technol (2010) 1.07
Single-cell and multivariate approaches in genetic perturbation screens. Nat Rev Genet (2014) 1.07
Tumor heterogeneity confounds and illuminates: assessing the implications. Nat Med (2014) 1.06
Tumor heterogeneity confounds and illuminates: a case for Darwinian tumor evolution. Nat Med (2014) 1.05
Quality assurance testing for modern optical imaging systems. Microsc Microanal (2011) 1.02
Mapping spatial heterogeneity in the tumor microenvironment: a new era for digital pathology. Lab Invest (2015) 0.98
A cell profiling framework for modeling drug responses from HCS imaging. J Biomol Screen (2010) 0.96
High-content screening with siRNA optimizes a cell biological approach to drug discovery: defining the role of P53 activation in the cellular response to anticancer drugs. J Biomol Screen (2004) 0.95
Systems cell biology knowledge created from high content screening. Assay Drug Dev Technol (2005) 0.94
Establishment and Molecular Cytogenetic Characterization of a Cell Culture Model of Head and Neck Squamous Cell Carcinoma (HNSCC). Genes (Basel) (2010) 0.92
De novo discovery of phenotypic intratumour heterogeneity using imaging mass spectrometry. J Pathol (2014) 0.91
Predicting rates of cell state change caused by stochastic fluctuations using a data-driven landscape model. Proc Natl Acad Sci U S A (2012) 0.89
Identifying network motifs that buffer front-to-back signaling in polarized neutrophils. Cell Rep (2013) 0.88
Calibrating excitation light fluxes for quantitative light microscopy in cell biology. Nat Protoc (2008) 0.86
Pipeline for illumination correction of images for high-throughput microscopy. J Microsc (2014) 0.83
Statistical issues in subpopulation analysis of high content imaging data. J Comput Biol (2010) 0.83
On comparing heterogeneity across biomarkers. Cytometry A (2014) 0.83
Emerging understanding of multiscale tumor heterogeneity. Front Oncol (2014) 0.82
Noise genetics: inferring protein function by correlating phenotype with protein levels and localization in individual human cells. PLoS Genet (2014) 0.81
Quantitative image correction and calibration for confocal fluorescence microscopy using thin reference layers and SIPchart-based calibration procedures. J Microsc (2008) 0.81
Rapid Assessment and Visualization of Normality in High-Content and Other Cell-Level Data and Its Impact on the Interpretation of Experimental Results. J Biomol Screen (2014) 0.79
Standardization, calibration, and control in flow cytometry. Curr Protoc Cytom (2005) 0.79
Analysis of chemotherapeutic response heterogeneity and drug clustering based on mechanism of action using an in vitro assay. Anticancer Res (2010) 0.78